CO6592108A2 - Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular - Google Patents
Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocularInfo
- Publication number
- CO6592108A2 CO6592108A2 CO12140238A CO12140238A CO6592108A2 CO 6592108 A2 CO6592108 A2 CO 6592108A2 CO 12140238 A CO12140238 A CO 12140238A CO 12140238 A CO12140238 A CO 12140238A CO 6592108 A2 CO6592108 A2 CO 6592108A2
- Authority
- CO
- Colombia
- Prior art keywords
- intraocular pressure
- alpha
- long duration
- reducing effect
- adrenergic agonist
- Prior art date
Links
- 230000004410 intraocular pressure Effects 0.000 title abstract 4
- 230000001603 reducing effect Effects 0.000 title abstract 2
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 title 1
- JHOJNZYPXCAPKL-UHFFFAOYSA-N 4-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-1h-benzimidazol-5-amine Chemical compound C1=CC=2NC=NC=2C(Br)=C1N=C1NCCN1 JHOJNZYPXCAPKL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29691210P | 2010-01-21 | 2010-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6592108A2 true CO6592108A2 (es) | 2013-01-02 |
Family
ID=44169074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12140238A CO6592108A2 (es) | 2010-01-21 | 2012-08-17 | Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9889088B2 (enExample) |
| EP (1) | EP2525793B1 (enExample) |
| JP (3) | JP2013518051A (enExample) |
| KR (1) | KR20120125305A (enExample) |
| CN (1) | CN102770135A (enExample) |
| AU (1) | AU2011207301A1 (enExample) |
| BR (1) | BR112012018154A2 (enExample) |
| CA (1) | CA2787573A1 (enExample) |
| CL (1) | CL2012002038A1 (enExample) |
| CO (1) | CO6592108A2 (enExample) |
| IL (1) | IL221030A0 (enExample) |
| MX (1) | MX2012008516A (enExample) |
| RU (1) | RU2012134065A (enExample) |
| SG (1) | SG182637A1 (enExample) |
| TW (1) | TW201141477A (enExample) |
| WO (1) | WO2011091225A2 (enExample) |
| ZA (1) | ZA201205470B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| BR112014001501A2 (pt) * | 2011-07-22 | 2017-02-14 | Allergan Inc | moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| TWI699205B (zh) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
| WO2019004080A1 (ja) | 2017-06-27 | 2019-01-03 | 国立大学法人東京大学 | 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| PT4236932T (pt) * | 2020-11-02 | 2026-02-23 | Visus Therapeutics Inc | Composto degradante num medicamento |
| WO2023086878A1 (en) * | 2021-11-10 | 2023-05-19 | Visus Therapeutics, Inc. | Carbachol formulations to enhance anti-presbyopia effects |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| AU704972B2 (en) * | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| US6495583B1 (en) * | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| CA2603044A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Alpha-2 adrenergic agonists for the treatment of pain |
| CA2641501A1 (en) | 2006-02-06 | 2007-08-16 | Nicox S.A. | Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
-
2011
- 2011-01-21 MX MX2012008516A patent/MX2012008516A/es unknown
- 2011-01-21 JP JP2012550140A patent/JP2013518051A/ja active Pending
- 2011-01-21 KR KR1020127021719A patent/KR20120125305A/ko not_active Withdrawn
- 2011-01-21 AU AU2011207301A patent/AU2011207301A1/en not_active Abandoned
- 2011-01-21 CN CN2011800111530A patent/CN102770135A/zh active Pending
- 2011-01-21 TW TW100102411A patent/TW201141477A/zh unknown
- 2011-01-21 EP EP11702342.4A patent/EP2525793B1/en not_active Not-in-force
- 2011-01-21 RU RU2012134065/15A patent/RU2012134065A/ru unknown
- 2011-01-21 BR BR112012018154A patent/BR112012018154A2/pt not_active IP Right Cessation
- 2011-01-21 WO PCT/US2011/022001 patent/WO2011091225A2/en not_active Ceased
- 2011-01-21 CA CA2787573A patent/CA2787573A1/en not_active Abandoned
- 2011-01-21 US US13/010,958 patent/US9889088B2/en not_active Expired - Fee Related
- 2011-01-21 SG SG2012053815A patent/SG182637A1/en unknown
-
2012
- 2012-07-19 IL IL221030A patent/IL221030A0/en unknown
- 2012-07-20 ZA ZA2012/05470A patent/ZA201205470B/en unknown
- 2012-07-20 CL CL2012002038A patent/CL2012002038A1/es unknown
- 2012-08-17 CO CO12140238A patent/CO6592108A2/es not_active Application Discontinuation
-
2015
- 2015-10-28 JP JP2015211447A patent/JP2016026206A/ja active Pending
-
2017
- 2017-04-26 JP JP2017086952A patent/JP6466504B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG182637A1 (en) | 2012-08-30 |
| ZA201205470B (en) | 2013-05-29 |
| CA2787573A1 (en) | 2011-07-28 |
| WO2011091225A3 (en) | 2012-05-18 |
| JP6466504B2 (ja) | 2019-02-06 |
| JP2013518051A (ja) | 2013-05-20 |
| KR20120125305A (ko) | 2012-11-14 |
| US9889088B2 (en) | 2018-02-13 |
| JP2017125074A (ja) | 2017-07-20 |
| BR112012018154A2 (pt) | 2016-04-05 |
| AU2011207301A1 (en) | 2012-08-09 |
| TW201141477A (en) | 2011-12-01 |
| EP2525793A2 (en) | 2012-11-28 |
| WO2011091225A2 (en) | 2011-07-28 |
| IL221030A0 (en) | 2012-09-24 |
| US20110178145A1 (en) | 2011-07-21 |
| CN102770135A (zh) | 2012-11-07 |
| JP2016026206A (ja) | 2016-02-12 |
| MX2012008516A (es) | 2012-10-15 |
| RU2012134065A (ru) | 2014-02-27 |
| EP2525793B1 (en) | 2018-09-05 |
| CL2012002038A1 (es) | 2012-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32183A (es) | Combinacion de una insulina y un agonista de glp-1 | |
| CY1122648T1 (el) | Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη | |
| CY1121041T1 (el) | Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| CL2012000348A1 (es) | Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica. | |
| GT201200217A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
| BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
| CL2011001529A1 (es) | Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende. | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| ES2721900T3 (es) | Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato | |
| TN2011000281A1 (en) | Dosage regimen of an s1p receptor agonist | |
| FI20116138A7 (fi) | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen | |
| BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
| BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
| MX2013002422A (es) | Sales de lorcaserina con acidos opticamente activos. | |
| BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
| BR112012018154A2 (pt) | agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular | |
| MX381776B (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| MX368880B (es) | Dexmedetomidina y medetomidina para su uso en el alivio de la aversión al ruido en un animal. | |
| MX376496B (es) | Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival. | |
| BR112015026259A2 (pt) | combinações de ligantes de adrenoceptor alfa-2 e receptor sigma | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| AR090929A1 (es) | Identificacion de la respuesta de un paciente a la administracion del modulador del receptor de s1p |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |